It is very fitting that on World Lung Cancer Day we can announce the approval of the MERU study, a new trial for patients with extensive stage Small Cell Lung Cancer. The MERU study will evaluate the efficacy of rovalpituzumab tesirine (Rova-T) as maintenance therapy following first-line platinum-based chemotherapy. More details about the trial can be found here.
Affinity will also be conducting a trial for patients with Non-small cell lung cancer in the coming months using the new drug Veliparib. More details can be found here.
To find out if you are eligible or for more information, you can contact our Research Nurses on (08) 9446 8726 or email info@affinityresearch.com.au
#wlcd #lungcancer #clinicaltrials
